Emkay Global ne Sagility India par coverage start kar di hai, Buy rating dete hue ₹55 ka target set kiya hai. US healthcare market ki demand ke chalte company ke **15%** growth ka estimate hai.
Kya hai story?
Emkay Global Financial ne ab Sagility India ko track karna shuru kar diya hai aur stock par 'Buy' rating di hai. Brokerage ne agle 12 mahino ke liye ₹55 ka target rakha hai. Unka manna hai ki company US healthcare market ki badhti demand aur wahan ke complex regulatory changes ka fayda uthane ke liye bilkul ready hai.
Business Model ka khel
Sagility India ka 90% revenue sirf US ke healthcare payers se aata hai. Kyunki US healthcare system mein rules bahut strict hain aur kharche badh rahe hain, toh wahan ki companies outsourcing partners par zyada depend karti hain. Isi wajah se Sagility ke paas long-term contracts hain jo steady income dete hain.
Growth ke projections
Brokerage ko umeed hai ki FY26 se FY29 ke beech company ka revenue har saal 15% ke rate se badhega. Operating margins 18.1% tak pahunch sakte hain, jisse earnings per share mein har saal 20% ka jump dikh sakta hai.
Risk factor ko ignore mat karna!
Sab kuch bullish nahi hai. Sabse bada risk ye hai ki inka business kuch hi bade US clients par tikka hai. Agar wahan koi policy change hua ya contract hath se nikla, toh revenue par seedha asar padega. Saath hi, market mein price war ka pressure bhi rehta hai. Emkay ne ye target 18 times expected earnings ke basis par calculate kiya hai, toh ab nazar is baat par honi chahiye ki ye apni efficiency kaise maintain karte hain.